Deadly Brain Cancer Genes Identified
By LabMedica International staff writers Posted on 06 Jun 2016 |
Image: The G2565BA microarray scanner system (Photo courtesy of Agilent Technologies).
Gliomas are a type of tumor that starts in the glial cells of the central nervous system, the brain and spinal cord, and glia are the support cells of the nervous system, providing physical support and insulation to neurons.
Glioblastoma multiforme, also known as grade 4 astrocytoma, is the most common and aggressive form of glioma and for this subtype of cancer, patients rarely survive much longer than a year from diagnosis, even when surgery, radiation, and chemotherapy are used, prognosis is poor.
Scientists at the First Hospital of China Medical University (Shenyang, People's Republic of China) examined tissue samples from 297 people with brain tumors and of these, 127 people had glioblastoma and the others had less aggressive forms of glioma. All tissue samples were immediately snap-frozen in liquid nitrogen after surgery.
A hematoxylin and eosin–stained frozen section was prepared from each sample to assess the percentage of tumor cells before ribonucleic acid (RNA) extraction. RNA concentration and quality were measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). Microarrays were prepared and the integrity of total RNA was checked using an Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and data were acquired using Agilent’s G2565BA microarray scanner system.
In all, the team analyzed 322 genes involved in the immune system and after extensive screening; eight specific genes were identified as playing a significant role in glioblastoma multiforme. Three of the eight genes were shown to have a protective role, while the other five increased the risk of earlier death. The scientists were able to construct a genetic signature that predicted the survival times of the patients and divide them into low- and high-risk groups.
Even after controlling for factors such as treatment type, those in the high-risk genetic group were twice more likely to have a shorter survival time than those in the low-risk group. The high-risk group survived an average of 348 days after diagnosis while the low-risk group survived an average of 493 days. Those in the high-risk group were also likely to have a shorter time between diagnosis and the first signs that the tumor was becoming worse, 242 days compared with 369 for the lower-risk group. The study was published on May 25, 2016, in the journal Neurology.
Related Links:
First Hospital of China Medical University
NanoDrop Technologies
Agilent Technologies
Glioblastoma multiforme, also known as grade 4 astrocytoma, is the most common and aggressive form of glioma and for this subtype of cancer, patients rarely survive much longer than a year from diagnosis, even when surgery, radiation, and chemotherapy are used, prognosis is poor.
Scientists at the First Hospital of China Medical University (Shenyang, People's Republic of China) examined tissue samples from 297 people with brain tumors and of these, 127 people had glioblastoma and the others had less aggressive forms of glioma. All tissue samples were immediately snap-frozen in liquid nitrogen after surgery.
A hematoxylin and eosin–stained frozen section was prepared from each sample to assess the percentage of tumor cells before ribonucleic acid (RNA) extraction. RNA concentration and quality were measured using the NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies). Microarrays were prepared and the integrity of total RNA was checked using an Agilent 2100 bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and data were acquired using Agilent’s G2565BA microarray scanner system.
In all, the team analyzed 322 genes involved in the immune system and after extensive screening; eight specific genes were identified as playing a significant role in glioblastoma multiforme. Three of the eight genes were shown to have a protective role, while the other five increased the risk of earlier death. The scientists were able to construct a genetic signature that predicted the survival times of the patients and divide them into low- and high-risk groups.
Even after controlling for factors such as treatment type, those in the high-risk genetic group were twice more likely to have a shorter survival time than those in the low-risk group. The high-risk group survived an average of 348 days after diagnosis while the low-risk group survived an average of 493 days. Those in the high-risk group were also likely to have a shorter time between diagnosis and the first signs that the tumor was becoming worse, 242 days compared with 369 for the lower-risk group. The study was published on May 25, 2016, in the journal Neurology.
Related Links:
First Hospital of China Medical University
NanoDrop Technologies
Agilent Technologies
Latest Molecular Diagnostics News
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer